Search results
Showing 1801 to 1835 of 1835 results for carers
NICE recommends life-changing gene therapy for children with ultra-rare genetic disorder
The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended by NICE.
The first in a new class of treatment to be recommended by NICE for treating acute migraine will soon be available on the NHS to around 13,000 people.
Children and young people need accurate, accessible information about their healthcare
New draft guidance from NICE recommends children and young people are fully informed about their health so that they can take an active role in their healthcare.
Angela sets out to understand some of the challenges, benefits and considerations of setting up and running a virtual ward, from the perspective of teams on the front lines.
NICE approves life-changing gene therapy for treating spinal muscular atrophy
A new one-off gene therapy for babies with the rare genetic disorder spinal muscular atrophy (SMA) is set to become the most expensive treatment ever approved by NICE.
Self-harm is everyone's business, NICE says in new draft guideline
All professionals working across the health and social care system have a role to play in supporting people who self-harm and the issue should not just be seen as the responsibility of those with mental health expertise, NICE has said in a new draft guideline.
Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS
Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.
New guidance aims to achieve fairer outcomes for looked-after children and young people
Looked after children and young people should be considered ‘one of their own’ by carers, to help them to reach their full potential, new NICE draft guidelines say.
NICE conditionally recommends 5 promising technologies for Parkinson's disease
These promising technologies could help improve symptoms and quality of life for people with Parkinson’s disease.
NICE recommends treatment for people with short bowel syndrome
A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above.
NICE recommends range of treatments for people with chronic primary pain
People with chronic primary pain should be offered a range of treatments to help them manage their condition.
NICE recommends novel treatment for debilitating inherited skin condition
Around 670 people in England with skin wounds caused by a rare inherited disorder to benefit from a new treatment to help the healing process.
NICE recommended treatment for Parkinson's set to benefit hundreds
Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved it for NHS use in final draft guidance published today (26 October 2023).
NICE outlines steps needed to put ME/CFS guideline into practice
NICE has today, (Thursday, 12 May 2022) published its implementation statement for its recent guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)
NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.
Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.
People who have had a stroke should be offered additional rehabilitation
People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover
Keep the size of your waist to less than half of your height, NICE recommends
People are being encouraged to keep their waist measurement to less than half their height to reduce the risk of potential health problems.
Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.
Adults with Von Hippel-Lindau disease to benefit from new treatment
NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.
New price deal paves way for NICE approval of treatment for rare genetic condition
A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
Three treatments for COVID-19 recommended in final draft guidance
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
Emergency kits for people with adrenal insufficiency recommended to avoid hospital admission
People with adrenal insufficiency should be given an emergency medical kit with potentially life-saving steroid injections, according to our new clinical guideline.
Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.
145,000 people in England to have further treatment choice for preventing migraine attacks
NICE has for the first time recommended an oral treatment for preventing migraines.
NICE publishes final draft guidance on Enhertu after commercial discussions conclude
NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.
Towards a new partnership – NICE and the voluntary and community sector
Victoria Thomas gives details of NICE’s new voluntary and community sector forum.
Children and young people set to benefit from new treatment for peanut allergy
Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.
How we can offer a broader range of benefits for people, their families and carers
NICE has been part of a research project investigating how quality of life measures used to evaluate healthcare treatments such as drugs can be extended into areas of social care and public health.
People with an acute respiratory infection offered monitoring from home
People with an acute respiratory infection (ARI) could be monitored from their own homes using technology platforms that will feedback vital information on their condition to clinical staff
NICE joins the shared commitment to public involvement in research
Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.